KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNTech SE (BNTX) Accounts Payables (2018 - 2025)

BioNTech SE's Accounts Payables history spans 8 years, with the latest figure at $622.6 million for Q4 2025.

  • On a quarterly basis, Accounts Payables rose 36.55% to $622.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $622.6 million, a 36.55% increase, with the full-year FY2025 number at $604.3 million, up 32.54% from a year prior.
  • Accounts Payables hit $622.6 million in Q4 2025 for BioNTech SE, up from $467.4 million in the prior quarter.
  • Over the last five years, Accounts Payables for BNTX hit a ceiling of $949.3 million in Q2 2024 and a floor of $32.1 million in Q1 2023.
  • Historically, Accounts Payables has averaged $381.5 million across 5 years, with a median of $317.6 million in 2024.
  • Biggest five-year swings in Accounts Payables: plummeted 76.88% in 2023 and later skyrocketed 911.45% in 2024.
  • Tracing BNTX's Accounts Payables over 5 years: stood at $183.0 million in 2021, then rose by 13.77% to $208.2 million in 2022, then soared by 82.91% to $380.9 million in 2023, then increased by 19.71% to $456.0 million in 2024, then surged by 36.55% to $622.6 million in 2025.
  • Business Quant data shows Accounts Payables for BNTX at $622.6 million in Q4 2025, $467.4 million in Q3 2025, and $570.7 million in Q2 2025.